Quality assessment of kidney cancer clinical practice guidelines using AGREE II instrument
A critical review

XiaoFeng Hou, MMa, Meixuan Li, MMb,c, Wenbo He, MMb, Meng Wang, MMb, Peijing Yan, MMd, Caiwen Han, MMb,c, Huijuan Li, MMb,c, Liujiao Cao, MMb,c, Biao Zhou, BMb, Zhenxing Lu, BMb, Bibo Jia, BMb, Jing Li, BMb, Xu Hui, BMb, Yunxia Li, MMg

Abstract
Background: Evidence-based guidelines are expected to provide clinicians with explicit recommendations on how to manage health conditions and bridge the gap between research and clinical practice. However, the existing practice guidelines (CPGs) vary in quality. This study aimed to evaluate the quality of CPGs of kidney cancer.

Methods: We systematically searched PubMed, Embase, China Biology Medicine disc, and relevant guideline websites from their inception to April, 2018. We identified CPGs that provided recommendations on kidney cancer; 4 independent reviewers assessed the eligible CPGs using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument. The consistency of evaluations was calculated using intraclass correlation coefficients (ICC).

Results: A total of 13 kidney cancer CPGs were included. The mean scores for each AGREE II domain were as follows: scope and purpose—76.9%; clarity and presentation—76.4%; stakeholder involvement—82.6%; rigor of development—76.4%; editorial independence—53.7%; and applicability—49.4%. Two CPGs were rated as “recommended”; 8 as “recommended with modifications”; and 3 as “not recommended.” Seven grading systems were used by kidney cancer CPGs to rate the level of evidence and the strength of recommendation.

Conclusions: Overall, the quality of CPGs of kidney cancer is suboptimal. AGREE II assessment results highlight the need to improve CPG development processes, editorial independence, and applicability in this field. It is necessary to develop a standardized grading system to provide clear information about the level of evidence and the strength of recommendation for future kidney cancer CPGs.

Abbreviations: AGREE II = Appraisal of Guidelines for Research and Evaluation, CI = confidence interval, CPGs = clinical practice guidelines, ICC = intraclass correlation coefficients, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, RCC = renal cell carcinoma.

Keywords: AGREE II, clinical practice guidelines, kidney cancer, quality assessment

1. Introduction
An estimated 62,700 Americans were diagnosed with kidney cancer and 14,240 died of the disease in 2016.1 The vast majority (greater than 90%) of kidney cancers are renal cortical tumors known as renal cell carcinoma (RCC).2 RCC comprises approximately 3.8% of all new cancers in the western world; the detection rate of RCC has been increasing in the past 10 years by approximately 1.7% per year.3 Since 2005, a number of new targeted agents have come into the market for the treatment of this disease.4 Although many of these therapies showing promising outcomes with improved progression-free survival and overall survival, diagnosis, treatment, and management of kidney cancer still remain the major challenge for clinicians.

Therefore, kidney cancer clinical practice guidelines (CPGs) drafted by local, national, and international organizations have been developed to standardize clinical practice and improve effectiveness of management. Ideally, evidence-based guidelines are expected to provide clinicians with explicit recommendations on how to manage health conditions and bridge the gap between research and clinical practice.5 However, the existing CPGs vary in quality and comprehensiveness, leading to difficulties with standardization of care, adaptation, and implementation, particularly in resource-limited settings. The usefulness of
guidelines primarily depends on the quality, rigorous methodology, and transparency of development. It is important to determine whether the recommendations are, indeed, based on high-quality evidence. At present, there is no literature comparing and evaluating the strengths and weaknesses of all available CPGs for the treatment of kidney cancer.

We aimed to assess and summarize the quality of all currently available international kidney cancer CPGs by conducting a critical review using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. We sought to identify gaps limiting evidence-based practice, and highlight potential opportunities for improvement.

2. Materials and methods

We conducted a comprehensive evaluation of kidney cancer CPGs using the AGREE II instrument, and the study was performed according to the guidelines from Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and some related studies. As it is a review of the previous works of literature, approval of the ethics committee was not required.

2.1. Search strategy

PubMed, Embase, and China Biology Medicine disc databases were systematically searched up to April, 2018. We combined the terms “kidney cancer,” “renal cell carcinoma,” “renal tumor,” and a filter to identify guideline documents (practice guideline [pt] OR guideline [pt] OR guideline* [ti]). We also searched the websites of guideline development organizations: Guidelines International Network Web site (http://www.g-i-n.net/), National Institute for Health and Care Excellence website (https://www.nice.org.uk/guidance), National Guideline Clearinghouse (https://guidelines.gov/), Scottish Intercollegiate Guidelines Network (http://www.sign.ac.uk/), Clinical Practice Guidelines Portal website (https://www.clinicalguidelines.gov.au/), New Zealand Guidelines Group website (https://www.health.govt.nz/), BCGuidelines website (http://www.bcguidelines.ca/alphabetical), AQuMed Database website (http://www.aezq.de/aezq/publications). In addition, we searched Google Search Engine and checked the references of all the related guidelines to include more potential guidelines.

2.2. Inclusion and exclusion criteria

The inclusion criteria were as follows: complete guideline text is available in English; guideline contains recommendations regarding kidney cancer interventions; and the guideline should be published after 2008. If the guideline had been updated, only the most recent version was assessed. For every guideline ultimately included, we thoroughly searched for accompanying technical and supporting documents to better inform our assessments. The following studies will be excluded: duplicate guidelines, guidelines for patients, editorials, secondary or multiple publications, and short summaries.

2.3. Guideline screening and data extraction

Two authors (L.M.X. and Y.P.J.) independently identified search results to determine eligibility guidelines, and extracted the basic information from included guidelines. Disagreements were resolved by consulting the third expert adjudicator (L.Y.X.).

2.4. Quality appraisal of guidelines

Four independent reviewers evaluated the quality of each kidney cancer CPG according to AGREE II instrument, which includes 23 items on a 7-point Likert scale across 6 domains. The standardization score for individual domain, which ranged from 0% to 100%, was calculated using the following formula: (actual score – minimal possible score)/(maximal possible score – minimal possible score) × 100%. AGREE II protocol states that no overall score is calculated to determine if a CPG is recommended or not recommended. Each guideline was classified as: “recommended” for overall scores >60%, “recommended with modifications” for scores between 30% and 60%, and “not recommended” for scores <30%.

2.5. Strength of recommendation and level of evidence

We extracted the level of evidence and the strength of recommendations of each kidney cancer guideline if they adopted evidence grading systems.

2.6. Statistical analysis

We calculated the standardized score of each domain for individual included CPGs, and determined the number of recommendations and the percentage distributions among quality of evidence and strength of recommendation classes. Agreement among 4 appraisers’ scores was tested using intraclass correlation coefficients (ICCs) with 95% confidence interval (CI) for each domain of all included guidelines. As a previous study described, the ICCs between 0.01 and 0.20 were considered minor, 0.21 to 0.40 fair, 0.41 to 0.60 moderate, 0.61 to 0.80 substantial, and 0.81 to 1.00 very good. A value of P < 0.05 indicated statistical significance. All tests were 2-sided. Statistical analyses were conducted using Excel2010 and SPSS version 21.0 (SPSS Inc., Chicago, IL).

3. Results

3.1. Study selection

Figure 1 shows the flow how we identified and selected the guidelines. The initial search yielded 1313 titles and abstracts, of which 126 were excluded as duplicates and 1108 were removed after reviewing abstracts. Full text identification was then performed on a total of 79 articles, of which only 13 met inclusion criteria.

3.2. CPG characteristics

A summary of the characteristics of the included CPGs was presented in Table 1. Thirteen kidney cancer guidelines were included in our study representing 12 different organizations and spanning several countries. Of these 13 CPGs, 9 were new, and the rest were updates; 1[2,4,18-28] were developed in high-income countries and only 1[1] was from middle-income country(China). The CPGs evaluated covered the different types of kidney cancers: 8 guidelines[14,20,22-25,27,28] focus on...
RCC, for renal mass and localized renal cancer, and for all stages of kidney cancer. The majority (8) of CPGs focused on the early management of kidney cancer, and others focused on the diagnosis, treatment, and follow-up.

3.3. CPG quality assessment (AGREE)

3.3.1. Consistency. The ICC values indicated that the overall agreement among 4 appraisers received higher reliability scores, ranging from 0.57 to 0.92 (Table 2). The ICCs for the AGREE appraisal conducted by the 4 reviewers was lowest in the “applicability” domain (0.57), highest in the “rigor of development” domain (0.92), and the overall assessment was 0.79, which indicated the intrareviewer item score agreement was good. Domain scores of the AGREE II quality assessment are illustrated in Table 2.

3.3.2. Domain 1: scope and purpose. This domain includes the main objectives of the CPGs, the health questions, and the target population. The mean score of kidney cancer CPGs in this domain is 76.9%, with a standard deviation (SD) of 9.5%, and all guidelines scored more than 50%. The lowest score was 63%, from SEOM clinical guideline for treatment of kidney cancer 2017 (SEOM, 2017). The highest score was 90.3%, from the use of targeted therapies in patients with inoperable locally advanced or metastatic renal cell cancer: updated guideline 2017 (PEBC, 2017).

3.3.3. Domain 2: stakeholder involvement. This domain focuses on the extent to which the CPG was developed by the appropriate stakeholders and represents the views of its intended users. Scores fluctuated remarkably with a mean score ± SD of 62.85% ± 17.4%. Two (15.4%) kidney cancer guidelines scored lower than 50%, of which the lowest was 24% from SEOM (SEOM, 2017).

3.3.4. Domain 3: rigor of development. This domain investigates the method and process of evidence search, grading, summary, and the formulation of the recommendations. The mean score and SD for this domain was 58.7% ± 18.4%. Three (23.1%) kidney cancer guidelines scored lower than 50%, of which the lowest was 27% from Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines (SOS, 2015).

3.3.5. Domain 4: clarity of presentation. This domain addresses the presentation and format of guidelines. The mean score and SD in this domain was 76.4% ± 13.8%. The lowest score was 50% from Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma (SOS, 2015).
### Table 1

The characteristics of included kidney cancer guidelines.

| Guideline          | Origin   | Version | Institution/guideline development group                                                                 | Focus of the guideline                      | Type of kidney cancer | Development method | Grading system used | Country income |
|--------------------|----------|---------|---------------------------------------------------------------------------------------------------------|---------------------------------------------|-----------------------|--------------------|--------------------|-----------------|
| SEOM, 2017          | Spain    | First   | Spanish Society of Medical Oncology and Spanish Oncology Genitourinary Group                           | Management of kidney cancer                | Kidney cancer         | CB                 | GRADE              | HIC             |
| SCAN, 2015          | Singapore| First   | The Singapore Cancer Network Genitourinary Cancer Workgroup                                            | Therapy of mRCC                             | RCC                   | EB                 | None               | HIC             |
| ASCO, 2017          | USA      | First   | American Society of Clinical Oncology                                                                | Management of Small Renal Masses           | Renal tumors          | EB                 | GLIDES             | HIC             |
| EAU, 2015           | Europe   | Update  | The European Association of Urology Renal Cell Cancer Guidelines Panel of the European Urology Association | Evaluation and management of renal masses  | Renal mass and localized renal cancer | EB                 | GRADE              | HIC             |
| PEBC, 2017          | Canada   | Update  | The Genitourinary Guideline Development Groups                                                         | Targeted therapies for locally advanced or mRCC | Inoperable locally advanced or metastatic RCC | EB                 | None               | HIC             |
| AUA, 2015           | USA      | Update  | Renal Cancer Guidelines Panel of the American Urological Association                                   | Follow-up and surveillance of the renal neoplasms | Localized renal neoplasms | EB                 | GRADE              | HIC             |
| NCCN, 2017          | International | Update | National Comprehensive Cancer Network                                                                | Management of cell renal carcinoma         | Clear cell and non-clear cell renal carcinoma | CB                 | NCCN               | HIC             |
| ESMO, 2016          | Europe   | Update  | European Society for Medical Oncology Chinese Society of Clinical Oncology                             | Clinical practice guidelines Management of RCC | RCC                  | EB                 | PHSGS              | HIC             |
| CSCO, 2015          | China    | Update  | Chinese Society of Clinical Oncology kidney cancer panel                                              | Management of cell renal carcinoma         | Clear cell and non-clear cell renal carcinoma | CB                 | NCCN               | HIC             |
| CIRSE, 2015         | Europe   | First   | Springer Science +Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe | CRSE Standards of practice guidelines      | Small RCC              | EB                 | CIRSE              | HIC             |
| AOS, 2012           | Asia     | First   | Asian Oncology Summit                                                                                  | Management of kidney cancer               | mRCC                  | EB                 | None               | All level       |
| SOS, 2015           | Saudi    | Update  | Saudi Oncology Society and Saudi Urology Association                                                  | Management of patients diagnosed with RCC  | RCC                   | EB                 | NA                 | HIC             |

CB = consensus-based, CIRSE = Cardiovascular and Interventional Radiological Society of Europe, EB = evidence-based, GRADE = Grading of Recommendations, Assessment, Development and Evaluation, HIC = high-income country, MIC = middle-income country, mRCC = metastatic renal cell cancer, NA = not available.

#### 3.3.6. Domain 5: Application

This domain focuses on processes related to CPG implementation such as organizational facilitators and barriers, additional materials provided, cost implications, and monitoring or audit criteria. The mean score and SD of this domain was 49.4% ± 21.6%, among which 4 kidney cancer guidelines scored less than 50%, with the lowest score of 3% from SEOM clinical guideline for treatment of kidney cancer (2017) (SEOM, 2017).

#### 3.3.7. Domain 6: editorial independence

This domain considers funders and competing interests of experts involved in guideline development. The mean score and SD of this domain was 53.7% ± 18.1%, and 5 scored less than 50%. The lowest score of 25% came from Cardiovascular and Interventional Radiological Society of Europe (CIRSE) guidelines on percutaneous ablation of small renal cell carcinoma (CIRSE, 2016) and SEOM clinical guideline for treatment of kidney cancer (SEOM, 2017). The highest score was 79.2%, from European Association of Urology Guidelines on Renal Cell Carcinoma 2015 (EAU, 2015).

#### 3.3.8. Overall assessment

This assessment concerns “the rating of body quality of the guidelines and whether the guideline would be recommended for use in practice.” According to the appraisal of the individual domains and overall scores, 2 kidney cancer guidelines overall scored >60%, and were rated as “recommended” by the appraisers; 8 were rated as “recommended with modifications”; and 3 as “not recommended” (Table 3).

#### 3.3.9. Level of evidence and strength of recommendation

Of the 13 included kidney cancer guidelines, 11 [2,4,20–28] of them were deemed evidence-based and 2 [18,19] were deemed expert consensus-based. Ten guidelines used grading systems to rate the level of evidence and the strength of recommendation, among which 3 [2,23,26] adopted Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) system (AUA,2017; AUA,2013; CSCO,2015), 1 [21] used GLIDES system (ASCO, 2017), 1 [15] used NCCN system (NCCN, 2017), 1 [24] used PHSGS system (ESMO, 2016), 1 [20] used CIRSE system (CIRSE, 2016), and 3[18,22,23] did not specify (SEOM, 2017; EAU, 2015; SOS, 2015). Whereas, the codes of level of evidence and strength of recommendation in different grading systems vary (Table 4).

4. Discussion
The study evaluated the quality of kidney cancer CPGs published after 2008, and 13 kidney cancer CPGs were included. Two guidelines were rated as “recommended,” 8 as “recommended with modifications,” and 3 as “not recommended.” Seven grading systems were used by kidney cancer CPGs to rate the level of evidence and the strength of recommendation.

There may exist some kidney cancer CPGs published before 2008[29,30] and were not updated, but the recommendations in those guidelines had been outdated and could not be used in practice according to IOM statements of CPGs.[31] Hence, we did not include these CPGs in this review. Among the 13 kidney cancer CPGs included, the highest mean scores were achieved in scope and purpose, stakeholder involvement, and clarity and presentation, whereas the main weaknesses across kidney cancer CPGs were rigor of development, applicability, and editorial independence. The European Association of Urology Guidelines on Renal Cell Carcinoma 2015 (EAU, 2015), The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017 (PBC, 2017), and Renal mass and localized renal cancer: AUA guideline (AUA, 2017) were the 3 CPGs with best results. Most of the included CPGs were developed by high-income countries, and are therefore minimally applicable in resource-limited settings. Apart from this, the distribution of level of evidence and strength of recommendations varied significantly among different kidney cancer CPGs.

The appraisal CPGs obtained the lowest score in applicability domain, suggesting that guideline developers have not paid sufficient attention to potential barriers affecting practical implementation of recommendations. Therefore, it is recommended that there should be a pilot test for the applicability of new guidelines before the release of clinical practice to ensure their feasibility. Guideline groups should provide recommendations and address the barriers as much specificity as the evidence permits.[32] The guideline developed by AUA (2017)[2] was recommended (scoring 68.8%) in our appraisal as a good example in future guideline development for this domain.

Kidney cancer CPGs also performed poorly in editorial independence domain, information related to potential conflicts of interest was scarce or not even mentioned, especially the guidelines developed by SEOM, CIRSE, SOS, and AOS. Because the conflicts of interest are the most common source of bias and often under-reported, CPG developers should explicitly declare whether potential conflicts of interest (such as between editorial board and pharmaceutical or medical device manufacturer) will impact on guideline drafting, including the rigorous vetting process and the transparent and available rules for review. Recently, some studies have reported that developers of CPGs were affected by pharmaceutical or medical device manufacturers, so it is important to know how much these interactions could have affected the recommendations.[33,34]

Rigor of CPGs mainly focuses on the methodological process of guidelines development, because this domain can better reflect the quality of CPGs than the other 5 domains. Even though vast majority of guidelines contained references, many did not explicitly describe literature search and selection methods, and were ambiguous regarding how to appraise evidence and formulate recommendations. This step is crucial to determine whether the recommendations really depend on the best available evidence. The low score might be caused by the poor methodology and reporting, or unfamiliarity with criteria of CPG development, or missing performance of external peer review and updating process.

As we all know, adaptation of existing guidelines to clinical practice may be a more valid and cost-effective means of achieving high-quality guidelines worldwide.[35] To achieve this aim, the majority of guidelines applied grading systems to rate the quality of evidence so as to communicate clear message, quickly and concisely to help guideline users, readers, and stakeholders to
## Table 4
Grading systems used in the included guidelines.

| Grading system used | Level of evidence | Definition of evidence level | Strength of recommendation | Definition of recommendation strength |
|---------------------|-------------------|-----------------------------|---------------------------|--------------------------------------|
| **SEOM, 2017**[18]  | I, II, III, IV, V | I—Evidence from at least 1 large randomized controlled trial of good methodological quality or meta-analyses of well-conducted randomized trials without heterogeneity. II—Small randomized trials or large randomized trials with a suspicion of bias or meta-analyses of such trials or of trials with demonstrated heterogeneity. III—Prospective cohort studies. IV—Retrospective cohort studies or case-control studies. V—Studies without control group, case reports, experts opinions. | A, B, C, D, E | A—Strong evidence for efficacy with a substantial clinical benefit, strongly recommended. B—Strong or moderate evidence for efficacy, but with a limited clinical benefit, generally recommended. C—Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages; optional. D—Moderate evidence against efficacy or for adverse outcome, generally not recommended. E—Strong evidence against efficacy or for adverse outcome, never recommended. |
| **ASCO, 2017**[21]  | High, intermediate, low, insufficient | High—The available evidence reflects the true magnitude and direction of the net effect and that further research is very unlikely to change either the magnitude or direction of this net effect. Moderate—The available evidence reflects the true magnitude and direction of the net effect. Further research is unlikely to alter the direction of the net effect; however, it might alter the magnitude of the net effect. Low confidence that the available evidence reflects the true magnitude and direction of the net effect. Further research may change either the magnitude and/or direction this net effect. Insufficient evidence is insufficient to discern the true magnitude and direction of the net effect. Further research may better inform the topic. The use of the consensus opinion of experts is reasonable to inform outcomes related to the topic. | Strong, moderate, weak | Strong—There is high confidence that the recommendation reflects best practice. This is based on strong evidence for a true net effect; consistent results with no or minor exceptions; minor or no concerns about study quality; and/or the extent of Expert Panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature review and analyses) may also warrant a strong recommendation. Moderate—There is moderate confidence that the recommendation reflects best practice. This is based on good evidence for a true net effect; consistent results, with minor and/or few exceptions; minor and/or few concerns about study quality; and/or the extent of Expert Panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature review and analyses) may also warrant a moderate recommendation. Weak—There is some confidence that the recommendation offers the best current guidance for practice. This is based on limited evidence for a true net effect (e.g., benefits exceed harms); consistent results, but with important exceptions; concerns about study quality; and/or the extent of Expert Panelists’ agreement. Other considerations (discussed in the guideline’s literature review and analyses) may also warrant a weak recommendation. |
| **EAU, 2015**[22]  | 1a, 1b, 2a, 2b, 3 A (high), B (moderate), C (low) NR | Grade A well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings. Grade B RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings. Grade C RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data. NR Strong recommendations are directive statements that an action should (benefits outweigh risks/burden) or should not (risks/burden outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate recommendations are directive statements that an action should (benefits outweigh risks/burden) or should not (risks/burden outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional recommendations are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear. | A, B, C | A, B, C |
| **AUA, 2017**[23]  | NR | NR | A, B, C | A, B, C |

(continued)
| Guideline | Grading system used | Level of evidence | Definition of evidence level | Strength of recommendation | Definition of recommendation strength |
|-----------|---------------------|-------------------|-----------------------------|---------------------------|--------------------------------------|
| AUA, 2013[26] | GRADE | A (high B (moderate), C (low)) | Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings) Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings) Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data). | Standard, option, clinical principle, expert opinion | Standard—Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on grade A or B evidence Recommendation—Directive statement that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be taken based on grade C evidence Option—Non-directive statement that leaves the decision regarding an action up to the individual clinician and patient because the balance between benefits and risks/burdens appears equal or appears uncertain based on grade A, B, or C evidence Clinical principle: A statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature Expert opinion: A statement, achieved by consensus of the Panel, that is based on members’ clinical training, experience, knowledge, and judgment for which there is no evidence |
| NCCN, 2017[18] | NCCN | 1, 2A, 2B, 3 | Category 1—Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A—Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B—Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3—Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. | NR | NR |
| ESMO, 2016[24] | Infectious Diseases Society of America, United States Public Health Service Grading System (PHSGS) | I, II, III, IV, V | I—Evidence from at least one large randomized controlled trial of good methodological quality or meta-analyses of well-conducted randomized trials without heterogeneity II—Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity III—Prospective cohort studies IV—Retrospective cohort studies or case-control studies V—Studies without control group, case reports, experts opinions | A, B, C, D, E | A—Strong evidence for efficacy with a substantial clinical benefit, strongly recommended B—Strong or moderate evidence for efficacy, but with a limited clinical benefit, generally recommended C—Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc), optional D—Moderate evidence against efficacy or for adverse outcome, generally not recommended E—Strong evidence against efficacy or for adverse outcome, never recommended |
| CSCO, 2015[23] | GRADE | 1, 2A, 2B, 3 | 1—Based upon high-level evidence, there is uniform CSCO consensus that the intervention is appropriate 2A—Based upon lower-level evidence, there is uniform CSCO kidney cancer panel consensus that the intervention is appropriate 2B—Based upon lower-level evidence, there is CSCO kidney cancer panel consensus that the intervention is appropriate 3—Based upon any level of evidence, there is major CSCO kidney cancer panel disagreement that the intervention is appropriate. | | |
understand the confidence of estimate of the effects and the strength of recommendations. The confidence of estimate of the effects reflects the extent to which confidence in an estimate of the effect is adequate to support a particular recommendation. Also, the strength of guideline recommendation reflects the extent of collective confidence that adherence to the recommendation will do more good than harm.\(^{16,37}\) However, we found different grading systems with various systems of codes were used to rate evidence and recommendations in kidney cancer CPGs, which could confuse the guideline users to apply these guidelines. Therefore, it is important to develop a standardized grading system to provide clear information about the level of evidence and the strength of recommendation for kidney cancer CPG users, and good news is that we find some guideline organizations such as the American Urological Association (AUA) begin to adopt GRADE system instead of old systems in their new version of guideline development handbooks.\(^{2,26}\)

There are several strengths of our findings. On the one hand, the strength of recommendations and level of evidence of each kidney cancer guideline were carefully extracted if these guidelines adopted evidence grading systems, which may indicate the overall quality of kidney cancer guidelines; On the other hand, our authors have different academic backgrounds, including methodological and medical experts, which ensured the reliability of our conclusions.

Inevitably, our study has some limitations: Firstly, we only included guidelines published in English; guidelines for some other languages are not included and may affect the universality of the results. Secondly, AGREE II instrument places emphasis on methods of guideline development and the transparency of reporting, but could not assess potential impacts of recommendations on patient outcomes.\(^{38,39}\)

5. Conclusions

Our analysis of current CPGs for the kidney cancer revealed that methodological quality of CPGs was acceptable, but there is still plenty of space for improvement, especially in the editorial independence, applicability, and rigor of development in the CPG development. Kidney cancer CPGs should develop recommendations with the evidence of high quality, while minimizing bias with compelling methodological rigor, openness, and transparency. If possible, CPGs should underline the demand for additional studies to close the gaps in clinical care that has a significant effect on patient outcomes.

Author contributions

Data curation: Xiaofeng Hou, Meixuan Li, Peijing Yan, Meng Wang, Wenbo He, Caiwen Han, Huijuan Li, Liujiao Cao, Biao Zhou, Zhenxing Lu, Bibo Jia, Jing Li, Xu Hui.

Formal analysis: Xiaofeng Hou, Meixuan Li, Peijing Yan, Meng Wang, Wenbo He.

Methodology: Xiaofeng Hou, Meixuan Li, Peijin Yan, Yunxia Li.

Project administration: Yunxia Li.

Resources: Caiwen Han, Huijuan Li, Liujiao Cao, Biao Zhou, Zhenxing Lu, Bibo Jia, Jing Li, Xu Hui.

Software: Wenbo He, Huijuan Li.

Supervision: Yunxia Li.

Writing – original draft: Xiaofeng Hou, Meixuan Li, Meng Wang.
References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
[2] Campbell S, Uzzo RG, Allaf ME, et al. Renal mass and localized renal cancer: AUA guideline. J Urol 2017;198:520–9.
[3] http://search.cancer.gov/statfacts/html/kidrp.html. Accessed November 2015.
[4] Kanesvaran R, Ng QS, Tan MH, et al. Singapore cancer network (SCAN) guidelines for systemic therapy of metastatic renal cell carcinoma (mRCC). Ann Acad Med Singapore 2015;44:406–14.
[5] Bero LA, Grilli R, Grimshaw JM, et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465–8.
[6] Grol R, Glanzek FA, Burgers JS. Clinical practice guidelines: towards better quality guidelines and increased international collaboration. Br J Cancer 2003;89(supp 1):54–8.
[7] Isaac A, Saginur M, Hartling L, et al. Quality of reporting and evidence in American Academy of Pediatrics guidelines. Pediatrics 2013;131:732–8.
[8] Khan AR, Khan S, Zimmerman V, et al. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis 2010;51:1147–56.
[9] Brouwers M, Kho M, Browman G, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010;182:E839–42.
[10] Moher D, Liberat A, Tetzlaff J, et al. the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[11] Di Bisceglie AM, Ciardelli G, De Marinis L, et al. A critical review of hepatitis C treatment guidelines. Medicine (Baltimore) 2019;98:e14392.
[12] Li L, Tian JH, Tian HL, et al. Network meta-analyses could be improved by searching more sources and by involving a librarian. J Clin Epidemiol 2014;67:1001–7.
[13] Yao L, Sun R, Chen YL, et al. The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 2016;74:73–9.
[14] Brouwers MC, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting, and evaluation in healthcare. CMAJ 2010;182:E839–42.
[15] Jiang M, Guan WJ, Fang ZF, et al. A critical review of the quality of cough clinical practice guidelines. Chest 2016;150:777–88.
[16] Shroft P, Fleiss J. Intra-class correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420–8.
[17] Alonso-Coello P, Irion A, Solà I, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care 2010;19:e58.
[18] Gallardo E, Mendez-Vidal MJ, Perez-Gracia JL, et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol 2018;20:47–56.
[19] Motzer RJ, Jonasch E, Agarwal N, et al. kidney cancer, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:804–34.
[20] Krook M, Orsi F, Katsanos K, et al. CI-RSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol 2017;40:177–91.
[21] Finelli A, Ismaila N, Bro B, et al. Management of small renal masses: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:668–80.
[22] Powles T, Stachler M, Li J, et al. European Association of Urology guidelines for clear cell renal cancers that are resistant to vascular endothelial growth factor receptor-targeted therapy. Eur Urol 2016;70:705–6.
[23] Guo J, Ma J, Sun Y, et al. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chin Clin Oncol 2016;5:12.
[24] Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v58–68.
[25] Alghamdi A, Alkhateeb S, Alghamdi K, et al. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Urol Ann 2016;8:136–40.
[26] Donat SM, Diaz M, Bishoff JT, et al. Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013;190:407–16.
[27] The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017. Available at: https://www.guideline.gov/summaries/summary/51032.
[28] Chtiong E, Tay MH, Tan MH, et al. Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 2012;13:e482–91.
[29] Nakamoto T. Treatment guideline of renal cancer. Jpn J Clin Oncol 2003;5:559–63.
[30] Miller K. Renal cell carcinoma. Guidelines for diagnosis and treatment. Urol Int 1999;63:6–9.
[31] Steinberg E, Green SG, Campbell S, et al. Renal cancer. Guidelines for diagnosis and treatment. Urol Int 1999;63:6–9.
[32] Miller K. Renal cell carcinoma. Guidelines for diagnosis and treatment. Urol Int 1999;63:6–9.
[33] Conforti F, Cirocchi R, Ferrari S, et al. The use of targeted therapies in patients with inoperable locally advanced or metastatic renal-cell cancer. Eur Urol 2017;71:689–99.
[34] Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2004;328:1490.
[35] Fervers B, Burgers J, Haugh M, et al. Adaptation of clinical guidelines: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 1998;317:465–8.
[36] Grol R, Glanzek FA, Burgers JS. Clinical practice guidelines: towards better quality guidelines and increased international collaboration. Br J Cancer 2003;89(supp 1):54–8.
[37] Isaac A, Saginur M, Hartling L, et al. Quality of reporting and evidence in American Academy of Pediatrics guidelines. Pediatrics 2013;131:732–8.
[38] Khan AR, Khan S, Zimmerman V, et al. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis 2010;51:1147–56.
[39] Brouwers M, Kho M, Browman G, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010;182:E839–42.
[40] Moher D, Liberat A, Tetzlaff J, et al. the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[41] Di Bisceglie AM, Ciardelli G, De Marinis L, et al. A critical review of hepatitis C treatment guidelines. Medicine (Baltimore) 2019;98:e14392.
[42] Li L, Tian JH, Tian HL, et al. Network meta-analyses could be improved by searching more sources and by involving a librarian. J Clin Epidemiol 2014;67:1001–7.
[43] Yao L, Sun R, Chen YL, et al. The quality of evidence in Chinese meta-analyses needs to be improved. J Clin Epidemiol 2016;74:73–9.